Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash & Current Investments (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Cash & Current Investments for 6 consecutive years, with $12.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 42.57% to $12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Dec 2025, up 42.57% year-over-year, with the annual reading at $12.3 million for FY2025, 42.57% up from the prior year.
  • Cash & Current Investments hit $12.3 million in Q4 2025 for Insight Molecular Diagnostics, down from $19.4 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $59.8 million in Q1 2021 to a low of $866000.0 in Q4 2022.
  • Historically, Cash & Current Investments has averaged $21.4 million across 5 years, with a median of $18.7 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: tumbled 97.44% in 2022 and later surged 989.15% in 2023.
  • Year by year, Cash & Current Investments stood at $33.9 million in 2021, then crashed by 97.44% to $866000.0 in 2022, then soared by 989.15% to $9.4 million in 2023, then fell by 8.44% to $8.6 million in 2024, then surged by 42.57% to $12.3 million in 2025.
  • Business Quant data shows Cash & Current Investments for IMDX at $12.3 million in Q4 2025, $19.4 million in Q3 2025, and $24.3 million in Q2 2025.